The European Health Data Space holds significant promise for transforming healthcare, research and innovation across Europe. The main objectives of the EHDS, which the European Commission launched in 2022, revolve around improving healthcare delivery, research, policy-making and patient empowerment. One of its key promises is advancing research and public health decision-making by facilitating the creation of large-scale, high-quality health data sets, which are essential for developing new trea

NEW YORK, April 1, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in April: April 5-9: American Academy of Neurology (AAN) 2025 Annual Meeting. Members of Immunic's management, medical and preclinical teams will attend this meeting in San Diego, California.

STOCKHOLM, April 1, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission (EC) has decided to refer the marketing authorisation approval decision of lecanemab in the EU to the Appeal Committee. The final process for the EC decision on lecanemab's Marketing Authorisation Application (MAA) is underway, following the reconfirmation of the positive opinion for lecanemab's approval by the Committee for Medicinal Products for

PARIS, April 1, 2025 /PRNewswire/ -- At the European Lung Cancer Congress 2025 (ELCC) (Paris, France, March 26 to 29), Hengrui Pharmaceuticals presented the 5-year long-term follow-up data from the CameL-sq study-a randomized, double-blind, multicenter, phase III trial that evaluated the efficacy and safety of camrelizumab vs. placebo in combination with carboplatin and paclitaxel as first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC) with negative driver genes. The r

Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology breakthrough properties for its PAR2 biased negative allosteric modulator program Posters present the potential of GPCRs to modulate the tumor microenvironment and enhance anti-tumor immunity STRASBOURG, France, MONTREAL and BOSTON, April 1, 2025 /PRNewswire/ -- Domain Therapeutics ("Domain" or "the

When the transatlantic startup AIRNA launched in 2023, it was already years behind other companies that were trying to bring a new form of genetic medicine known as RNA editing into the clinic. But that competition hasn’t daunted AIRNA or its investors. On Tuesday, AIRNA announced that it has raised $155 million in Series B financing and plans to file a clinical trial application by the second half of this year. The new round, co-led by Venrock Healthcare Capital Partners and Forbion Growth, bri

April 1, 2025 -- A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment’s effectiveness in patients with metastatic gastrointestinal cancers, according to results of a clinical trial led by researchers at the National Institutes of Health (NIH). The findings, published April 1, 2025 in Nature Medicine , offer hope that this therapy could be used to treat a variety of solid tumors, which has so far eluded researc

TUESDAY, April 1, 2025 -- Microplastics appear to be contributing to chronic diseases in shoreline areas of the United States, a new study suggests. High blood pressure, diabetes and stroke rates are higher in coastal or lakefront areas with greater concentrations of microplastics in the environment, researchers reported at a meeting of the American College of Cardiology (ACC). The results also suggested a dose relationship, where higher concentrations of microplastics pollution are associated

TUESDAY, April 1, 2025 -- For patients with prostate cancer , isodose and dose-escalated moderately hypofractionated radiotherapy (MHFRT) have similar efficacy as conventionally fractionated radiotherapy (CFRT), but bowel toxicity is seen in association with dose-escalated MHFRT, according to a study published online March 17 in The Lancet Oncology . Amar U. Kishan, M.D., from the University of California, Los Angeles, and colleagues conducted an individual patient data meta-analysis from random

TUESDAY, April 1, 2025 -- Personalized support can help more people at risk of colon cancer attend a potentially life-saving colonoscopy appointment, a new study says. About 55% of people assigned a patient navigator got a follow-up colonoscopy after their stool test revealed a risk of colon cancer, compared with nearly 43% of patients who were simply notified of the abnormal test and given a referral, researchers reported March 31 in the Annals of Internal Medicine . “It is important for patie